0001209191-16-150176.txt : 20161115
0001209191-16-150176.hdr.sgml : 20161115
20161115162221
ACCESSION NUMBER: 0001209191-16-150176
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161110
FILED AS OF DATE: 20161115
DATE AS OF CHANGE: 20161115
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 222711928
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PEHL MICHAEL F.
CENTRAL INDEX KEY: 0001677939
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34912
FILM NUMBER: 161999962
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-11-10
0
0000816284
CELGENE CORP /DE/
CELG
0001677939
PEHL MICHAEL F.
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT
NJ
07901
0
1
0
0
See remarks
Common Stock
2016-11-10
4
M
0
938
36.36
A
2566
D
Common Stock
2016-11-10
4
M
0
781
114.08
A
3347
D
Common Stock
2016-11-10
4
M
0
1668
34.70
A
5015
D
Common Stock
2016-11-10
4
M
0
1668
36.68
A
6683
D
Common Stock
2016-11-10
4
M
0
1668
49.48
A
8351
D
Common Stock
2016-11-10
4
M
0
1876
59.24
A
10227
D
Common Stock
2016-11-10
4
M
0
1876
71.33
A
12103
D
Common Stock
2016-11-10
4
M
0
1876
78.12
A
13979
D
Common Stock
2016-11-10
4
M
0
1874
74.30
A
15853
D
Common Stock
2016-11-10
4
M
0
1250
87.64
A
17103
D
Common Stock
2016-11-10
4
M
0
625
103.10
A
17728
D
Common Stock
2016-11-10
4
M
0
1250
117.18
A
18978
D
Common Stock
2016-11-10
4
M
0
625
118.57
A
19603
D
Common Stock
2016-11-10
4
M
0
781
109.90
A
20384
D
Common Stock
2016-11-10
4
M
0
1668
36.47
A
22052
D
Common Stock
2016-11-10
4
S
0
20424
121.03
D
1628
D
Common Stock
2016-11-10
4
S
0
1628
121.15
D
0
D
Stock Option (right to buy)
36.36
2016-11-10
4
M
0
938
0.00
D
2022-01-30
Common Stock
938
0
D
Stock Option (right to buy)
114.08
2016-11-10
4
M
0
781
0.00
D
2025-11-09
Common Stock
781
2344
D
Stock Option (right to buy)
34.70
2016-11-10
4
M
0
1668
0.00
D
2022-07-30
Common Stock
1668
0
D
Stock Option (right to buy)
36.68
2016-11-10
4
M
0
1668
0.00
D
2022-10-31
Common Stock
1668
0
D
Stock Option (right to buy)
49.48
2016-11-10
4
M
0
1668
0.00
D
2023-01-28
Common Stock
1668
1668
D
Stock Option (right to buy)
59.24
2016-11-10
4
M
0
1876
0.00
D
2023-04-29
Common Stock
1876
1876
D
Stock Option (right to buy)
71.33
2016-11-10
4
M
0
1876
0.00
D
2023-07-29
Common Stock
1876
1876
D
Stock Option (right to buy)
78.12
2016-11-10
4
M
0
1876
0.00
D
2023-10-28
Common Stock
1876
1876
D
Stock Option (right to buy)
74.30
2016-11-10
4
M
0
1874
0.00
D
2024-02-03
Common Stock
1874
3752
D
Stock Option (right to buy)
87.64
2016-11-10
4
M
0
1250
0.00
D
2024-07-28
Common Stock
1250
2500
D
Stock Option (right to buy)
103.10
2016-11-10
4
M
0
625
0.00
D
2024-10-27
Common Stock
625
1250
D
Stock Option (right to buy)
117.18
2016-11-10
4
M
0
1250
0.00
D
2024-12-19
Common Stock
1250
3750
D
Stock Option (right to buy)
118.57
2016-11-10
4
M
0
625
0.00
D
2025-02-02
Common Stock
625
1875
D
Stock Option (right to buy)
109.90
2016-11-10
4
M
0
781
0.00
D
2025-05-04
Common Stock
781
2344
D
Stock Option (right to buy)
36.47
2016-11-10
4
M
0
1668
0.00
D
2022-04-30
Common Stock
1668
0
D
The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $120.99 to $121.22, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
The option was fully exercisable.
The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated on April 15, 2015).
President Hematology & Oncology
/s/ Peter N. Kellogg ________________________________________________________________
Peter N. Kellogg, Attorney-in-Fact
2016-11-14